Annovis Bio, Inc.

ANVS NYSE SEC CIK 1477845
Follow Annovis Bio Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$9.5M −30.3% vs same quarter last year
EPS, diluted −$0.22 +40.5% vs same quarter last year
Operating cash flow −$16M −359.8% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$28.9M
FY24$0−$24.6M
FY23$0−$56.2M
FY22$0−$25.3M
FY21$0−$14.5M
FY20$0−$5.5M
FY19$0−$991K
FY18--